US FDA requires new warnings for gadolinium-based contrast agents
This article was originally published in RAJ Devices
Executive Summary
US manufacturers of gadolinium-based contrast agents will have to change their product labels to include warnings about the risk of nephrogenic systemic fibrosis associated with the use of the drugs in patients with kidney disease, the Food and Drug Administration has said1,2.
You may also be interested in...
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
US FDA scrutiny of DTC genetic tests continues
The US FDA's devices unit has written to three genetic testing companies warning them that they may be marketing their products and services without clearance by the agency.